Impact Biomedical (IBO) Cash & Equivalents (2022 - 2026)
Impact Biomedical's (IBO) quarterly Cash & Equivalents came in at $20000.0 in Q1 2026, down 98.48% YoY from $1.3 million in Q1 2025, and up 566.67% on a QoQ basis from $3000.0 in Q4 2025.
Impact Biomedical (IBO) Cash & Equivalents (2022 - 2026) Analysis & Trends
Impact Biomedical (IBO) has 5 years of Cash & Equivalents data on file, last reported at $20000.0 in Q1 2026.
- Quarterly Cash & Equivalents fell 98.48% year-over-year to $20000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20000.0 (down 98.48% YoY) and the FY2025 annual result came in at $3000.0, down 99.85% from the prior year.
- Cash & Equivalents advanced to $20000.0 in Q1 2026, from $3000.0 in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $2.0 million in Q4 2024 to a low of $1000.0 in Q3 2023.
- A 5-year average of $335100.0 and a median of $2500.0 in 2022 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2024 — Cash & Equivalents surged 199800.0% — and 2025, when it tumbled 99.85%.
- Tracing IBO's Cash & Equivalents over 5 years: stood at $2000.0 in 2022, then slumped by 50.0% to $1000.0 in 2023, then surged by 199800.0% to $2.0 million in 2024, then plunged by 99.85% to $3000.0 in 2025, then surged by 566.67% to $20000.0 in 2026.
- The last three Cash & Equivalents figures came in at $20000.0 (Q1 2026), $3000.0 (Q4 2025), and $1.3 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.72 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.71 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.93 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 544.80 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 811.99 Mn |
| 10 | Impact Biomedical | 49.54 Mn | 49.53 Mn | 2,000.00 | 10,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10,000.00 |
| Mar 31, 2026 | 20,000.00 |
| Dec 31, 2025 | 3,000.00 |
| Mar 31, 2025 | 1.32 Mn |
| Dec 31, 2024 | 2.00 Mn |
| Jun 30, 2024 | 2,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Dec 31, 2023 | 1,000.00 |
| Sep 30, 2023 | 1,000.00 |
| Jun 30, 2023 | 3,000.00 |
| Dec 31, 2022 | 2,000.00 |